Supplemental
Subjects were further classified into 2 groups according to drug history (lipid-lowering agent non-user group and lipid-lowering agent user group). The patients' demographic and laboratory data are summarized in Supplemental Table 1 . Among the enrolled subjects, 50% and 27% of the T2D and IFG patients have taken lipid-lowering drugs, respectively. Total cholesterol, HDL-C, and LDL-C were significantly higher in subjects in the lipid-lowering agent non-user group. WC, WHR, and HOMA-IR were statistically lower in the lipid-lowering agent non-user group. Fasting and postprandial glucose and TG were not different between the 2 groups. BMI, body mass index; NS, not significant; WC, waist circumference; WHR, waist/hip ratio; TG, triglyceride; HDL-C, high density lipoprotein cholesterol; LDL-C, low density lipoprotein cholesterol; HOMA-IR, homeostatic model assessment of insulin resistance; HOMA-β, homeostatic model assessment of pancreatic β-cell function; IGI, insulinogenic index, T2D, type 2 diabetes; IFG, impaired fasting glucose. 
